ES2582557T3 - Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina - Google Patents

Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina Download PDF

Info

Publication number
ES2582557T3
ES2582557T3 ES13725042.9T ES13725042T ES2582557T3 ES 2582557 T3 ES2582557 T3 ES 2582557T3 ES 13725042 T ES13725042 T ES 13725042T ES 2582557 T3 ES2582557 T3 ES 2582557T3
Authority
ES
Spain
Prior art keywords
substituted
unsubstituted
compound
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13725042.9T
Other languages
English (en)
Spanish (es)
Inventor
David Askin
Chong Han
Jonathan W. LANE
Travis Remarchuk
Sagar Shakya
C. Gregory Sowell
Keith L. Spencer
Peter J. Stengel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Array Biopharma Inc
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2582557T3 publication Critical patent/ES2582557T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
ES13725042.9T 2012-05-17 2013-05-17 Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina Active ES2582557T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648473P 2012-05-17 2012-05-17
US201261648473P 2012-05-17
US201361785122P 2013-03-14 2013-03-14
US201361785122P 2013-03-14
PCT/US2013/041666 WO2013173768A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (1)

Publication Number Publication Date
ES2582557T3 true ES2582557T3 (es) 2016-09-13

Family

ID=48485537

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13725042.9T Active ES2582557T3 (es) 2012-05-17 2013-05-17 Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina

Country Status (20)

Country Link
US (4) US9416110B2 (https=)
EP (1) EP2861582B1 (https=)
JP (1) JP6284928B2 (https=)
KR (1) KR102067850B1 (https=)
CN (1) CN104470913B (https=)
AU (1) AU2013262505B2 (https=)
BR (1) BR112014028589B1 (https=)
CA (1) CA2873654C (https=)
DK (1) DK2861582T3 (https=)
ES (1) ES2582557T3 (https=)
IL (1) IL235715A (https=)
MX (1) MX353384B (https=)
MY (1) MY169028A (https=)
NZ (1) NZ702935A (https=)
PL (1) PL2861582T3 (https=)
RU (1) RU2643811C2 (https=)
SG (1) SG11201407616TA (https=)
SI (1) SI2861582T1 (https=)
WO (1) WO2013173768A1 (https=)
ZA (1) ZA201409261B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9416110B2 (en) 2012-05-17 2016-08-16 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
KR102678074B1 (ko) 2012-05-17 2024-06-26 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
ES2588878T3 (es) 2012-05-17 2016-11-07 Array Biopharma, Inc. Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
SI3068770T1 (sl) 2013-11-15 2020-02-28 F. Hoffmann-La Roche Ag Postopki za pripravo pirimidinilciklopentanskih spojin
RU2732404C2 (ru) * 2014-09-26 2020-09-16 Ф. Хоффманн-Ля Рош Аг СПОСОБЫ ПОЛУЧЕНИЯ (ЦИКЛОПЕНТИЛ[d]ПИРИМИДИН-4-ИЛ)ПИПЕРАЗИНОВЫХ СОЕДИНЕНИЙ
BR112019002007B1 (pt) 2016-08-10 2024-01-16 F. Hoffmann-La Roche Ag Composição farmacêutica e uso de uma composição farmacêutica
CN115916758A (zh) 2020-06-16 2023-04-04 豪夫迈·罗氏有限公司 用于制备羟基化环戊基嘧啶化合物的方法
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015684A1 (en) 1993-12-12 1995-06-15 Agrogene, Ltd. A novel method to protect plants from fungal infection
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
AU3386600A (en) 1999-03-03 2000-09-21 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE60020560T2 (de) * 1999-06-03 2006-04-27 Teikoku Hormone Mfg. Co., Ltd. Substituierte pyrazol-derivate
AU7715300A (en) 1999-09-27 2001-04-30 Merck & Co., Inc. Method of preventing osteoporosis
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
EA020151B1 (ru) * 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
ES2588878T3 (es) 2012-05-17 2016-11-07 Array Biopharma, Inc. Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
KR102678074B1 (ko) 2012-05-17 2024-06-26 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
HRP20180948T1 (hr) 2012-05-17 2018-08-10 Genentech, Inc. Postupak za proizvodnju aminokiselinskih spojeva
US9416110B2 (en) 2012-05-17 2016-08-16 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
US20140121193A1 (en) 2012-11-01 2014-05-01 Robert S. Katz Methods for treating fibromyalgia
CN105263910A (zh) 2013-02-18 2016-01-20 斯克利普斯研究所 具有治疗潜力的血管加压素受体调节剂
CN105473141A (zh) 2013-03-15 2016-04-06 实发生物医学公司 治疗和/或预防心血管疾病的抗pcsk9化合物和方法

Also Published As

Publication number Publication date
KR20150020214A (ko) 2015-02-25
HK1208451A1 (en) 2016-03-04
ZA201409261B (en) 2017-05-31
SG11201407616TA (en) 2015-03-30
KR102067850B1 (ko) 2020-01-17
CN104470913B (zh) 2018-07-20
EP2861582A1 (en) 2015-04-22
WO2013173768A1 (en) 2013-11-21
MY169028A (en) 2019-02-04
US9416110B2 (en) 2016-08-16
IL235715A0 (en) 2015-02-01
SI2861582T1 (sl) 2016-09-30
US9676730B2 (en) 2017-06-13
JP2015517532A (ja) 2015-06-22
CA2873654C (en) 2021-06-22
MX2014013862A (es) 2015-05-07
AU2013262505B2 (en) 2017-09-21
IL235715A (en) 2017-02-28
US20180258054A1 (en) 2018-09-13
RU2643811C2 (ru) 2018-02-06
US20150152067A1 (en) 2015-06-04
PL2861582T3 (pl) 2016-11-30
AU2013262505A1 (en) 2015-01-22
NZ702935A (en) 2017-02-24
CA2873654A1 (en) 2013-11-21
JP6284928B2 (ja) 2018-02-28
BR112014028589A2 (pt) 2017-07-25
US20170247337A1 (en) 2017-08-31
CN104470913A (zh) 2015-03-25
DK2861582T3 (en) 2016-08-22
US20160318877A1 (en) 2016-11-03
EP2861582B1 (en) 2016-05-25
MX353384B (es) 2018-01-10
RU2014151050A (ru) 2016-07-10
US9790190B2 (en) 2017-10-17
BR112014028589B1 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
ES2582557T3 (es) Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
JP5735659B2 (ja) シタグリプチンの中間体の製造方法
WO1999002500A1 (es) Resolucion de aminas
ES2668477T3 (es) Proceso de preparación de compuestos de aminoácidos
ES2749100T3 (es) Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina
JP2025026621A (ja) シス-(-)-フロシノピペリドールの製造方法
TW202237594A (zh) 製造5-(4-((2s,5s)-5-(4-氯芐基)-2-甲基嗎啉基)哌啶-1-基)-1h-1,2,4-三唑-3-胺的方法
HK1208451B (zh) 用於製造羥基化的環戊基嘧啶化合物的方法
HK40024946B (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK40024946A (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
CN103304538A (zh) 右旋甲氟喹的合成